This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
500mg | $1100 | Check With Us |
1g | $1650 | Check With Us |
5g | $4175 | Check With Us |
Cat #: V0456 CAS #: 305350-87-2 Purity ≥ 98%
Description: SL327 (SL-327) is a novel, potent and selective inhibitor for MEK1/2 with the ability to cross blood brain barrier and block fear conditioning.
References: Cheng Y, et al. Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10). pii: E1551.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 335.35 |
---|---|
Molecular Formula | C16H12F3N3S |
CAS No. | 305350-87-2 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
Solubility In Vitro | DMSO: 67 mg/mL (199.8 mM)r |
Water: <1 mg/mLr | |
Ethanol: 7 mg/mL (20.9 mM) | |
Solubility In Vivo | 2% DMSO+30% PEG 300+5% Tween 80+ddH2O: 5 mg/mL |
SMILES Code | N#C/C(C1=CC=CC=C1C(F)(F)F)=C(N)/SC2=CC=C(N)C=C2 |
Synonyms | SL 327; SL-327; SL327 |
Protocol | In Vitro | The specificity of SL327 for MEK is investigated. Kinase activity is assessed by measuring the incorporation of [32P]phosphate during phosphorylation of substrate peptides specific for each kinase. Although SL327 inhibits MEK with an IC50 of 0.27 μM, 10 μM SL327 has no significant effect on PKA, CaMKII, or PKC. |
---|---|---|
In Vivo | SL327, which crosses the blood-brain barrier, is administered intraperitoneally at several concentrations to animals prior to cue and contextual fear conditioning. Administration of SL327 completely blocks contextual fear conditioning and significantly attenuates cue learning when measure 24 hr after training. Animals treated with SL327 exhibit significant attenuation of water maze learning; they take significantly longer to find a hidden platform compared with vehicle-treated controls and also fail to use a selective search strategy during subsequent probe trials in which the platform is removed. Mice are injected with various concentrations of SL327 (10, 30, 50 mg/kg i.p.), and 1 hr later their hippocampi are removed and assayed for activated MAPK. SL327 attenuates phosphorylated MAPK levels in a dose-dependent manner. Administration of 10, 30, or 50 mg/kg SL327 significantly attenuates p42 phospho-MAPK levels (F=20.90, P<0.0001;10 mg/kg SL327 vs. vehicle, P<0.05, and 30 and 50 mg/kg SL327 vs. vehicle, P<0.001). Injection with 30 or 50 mg/kg SL327 also significantly reduces p44 phospho-MAPK levels (F=5.627, P<0.005;30 mg/kg vs. vehicle, P<0.05, and 50 mg/kg SL327 vs. vehicle, P<0.01). |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 2.9820 mL | 14.9098 mL | 29.8196 mL | 59.6392 mL |
5mM | 0.5964 mL | 2.9820 mL | 5.9639 mL | 11.9278 mL |
10mM | 0.2982 mL | 1.4910 mL | 2.9820 mL | 5.9639 mL |
20mM | 0.1491 mL | 0.7455 mL | 1.4910 mL | 2.9820 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.